{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=93", "query": { "condition": "Advanced Solid Neoplasm", "page": 93 }, "page_size": 10 }, "pagination": { "page": 93, "page_size": 10, "total_count": 3387, "total_pages": 339, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=94&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=92&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T21:40:00.901Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04800822", "title": "PF-07284892 in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "PF-07284892", "type": "DRUG" }, { "name": "lorlatinib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "encorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2021-03-17", "completion_date": "2024-06-19", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-11-14T21:40:00.901Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04800822" }, { "nct_id": "NCT04505839", "title": "First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "STP1002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ST Pharm Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2020-07-30", "completion_date": "2023-03-07", "has_results": false, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-11-14T21:40:00.901Z", "location_count": 3, "location_summary": "Los Angeles, California • Denver, Colorado • Evanston, Illinois", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04505839" }, { "nct_id": "NCT00003242", "title": "Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "bryostatin 1", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-02", "completion_date": "2001-10", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-11-14T21:40:00.901Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003242" }, { "nct_id": "NCT03666273", "title": "Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Bapotulimab (BAY1905254)", "type": "DRUG" }, { "name": "Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2018-09-12", "completion_date": "2024-05-15", "has_results": false, "last_update_posted_date": "2024-05-28", "last_synced_at": "2026-11-14T21:40:00.901Z", "location_count": 8, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03666273" }, { "nct_id": "NCT06939283", "title": "A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "WTX-330", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Werewolf Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-04-21", "completion_date": "2026-04-23", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-14T21:40:00.901Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06939283" }, { "nct_id": "NCT02257476", "title": "Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Malignancies" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2014-08", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-11-14T21:40:00.901Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02257476" }, { "nct_id": "NCT05691517", "title": "Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "pH Low Insertion Peptide-exatecan Conjugate CBX-12", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2024-06-12", "completion_date": "2028-10-15", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-14T21:40:00.901Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05691517" }, { "nct_id": "NCT01209143", "title": "A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" }, { "name": "Rosiglitazone", "type": "DRUG" }, { "name": "Norethindrone/ethinyl estradiol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2010-11", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2015-06-29", "last_synced_at": "2026-11-14T21:40:00.901Z", "location_count": 3, "location_summary": "Stanford, California • Detroit, Michigan • Houston, Texas", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01209143" }, { "nct_id": "NCT06907043", "title": "A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "EIK1004-001 (IMP1707-001)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 130, "start_date": "2025-04-30", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-08-19", "last_synced_at": "2026-11-14T21:40:00.901Z", "location_count": 6, "location_summary": "Denver, Colorado • Lake Mary, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06907043" }, { "nct_id": "NCT06096974", "title": "Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "YL-17231", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai YingLi Pharmaceutical Co. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2023-10-24", "completion_date": "2026-04", "has_results": false, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-11-14T21:40:00.901Z", "location_count": 3, "location_summary": "Cincinnati, Ohio • Houston, Texas • Salt Lake City, Utah", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06096974" } ] }